The eye structure is delicate and complex, and high-end ophthalmic medical equipment is key to achieving precise diagnosis and treatment. High-end ophthalmic medical equipment can not only detect potential eye diseases as early as possible and assist doctors in managing them, helping to reduce the burden of eye diseases and blindness risks. It can also improve diagnostic accuracy, lower surgical risks, enhance surgical safety and success rates, and significantly improve treatment outcomes.
High-end ophthalmic medical equipment includes high-value and technologically advanced diagnostic and treatment devices such as ophthalmic surgical microscopes, ophthalmic optical coherence tomography (OCT), ophthalmic optical biometry instruments, ultra-wide-angle fundus cameras, super-ultra-wide-angle vitrectomy integrated machines, femtosecond lasers, etc., which are widely used in the diagnosis and treatment of ophthalmic diseases.
In recent years, driven by continuous national policies, the development of China's ophthalmic medical equipment industry has made remarkable progress. Domestic high-end ophthalmic medical equipment has been continuously emerging, and the process of localization substitution has been accelerating. In the field of high-end ophthalmic medical equipment, localization substitution has been achieved, and in some areas, advantageous substitution has taken place, creating more welfare for society.
Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') has officially released the 'Blue Book on the Current Situation and Future Development Trends of High-End Ophthalmic Medical Equipment Industry' (hereinafter referred to as the 'Blue Book'). The report aims to analyze the current situation of the high-end ophthalmic medical equipment industry, comprehensively display the industry's technological development, application fields, and listed products, tap into the huge potential of industry development, analyze the driving factors behind market development and future trends, with the aim of providing reference for participants and stakeholders in the high-end ophthalmic medical equipment industry.
1
Overview of Eye Diseases
01 Overview of Eye Structure and Ophthalmic Diseases
Eye diseases are prevalent globally, and eye disorders and visual impairment are very common. Common eye diseases such as cataracts, glaucoma, and diabetic retinopathy pose a risk of blindness to patients. The healthcare needs span the entire life cycle of eye diseases.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the structure of the eye, defines common ophthalmic diseases, their hazards, and treatment methods. For more detailed content, please refer to the full report.
02 Eye diseases have become a major global health concern for humanity
Factors such as population growth, aging, and changes in modern lifestyles have driven an increase in the number of patients with eye diseases globally. According to data from The Lancet Global Health, by 2050, 5 billion people will be affected by myopia. By then, about 895 million people globally will suffer from distant vision impairment, with 61 million potentially becoming blind due to eye diseases. Eye diseases urgently need prevention and treatment to achieve global sustainable development goals.
03 China has a large base of ophthalmic disease patients, and policies are helping to boost the development of the ophthalmic industry.
The burden of eye diseases in China is severe, and ophthalmic diseases have become a major public health challenge in the country. Diseases such as cataracts, glaucoma, and age-related macular degeneration carry a high burden and the number of patients is increasing year by year, leading to significant unmet clinical needs. The penetration rate of common ophthalmic surgeries such as cataract surgery and the screening capabilities for key ophthalmic diseases need further improvement. High-end ophthalmic medical equipment can effectively prevent and control the progression of eye diseases and significantly improve the quality of ophthalmic surgeries, but its prevalence and use are relatively low in middle- and low-income areas and primary healthcare institutions.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the global and Chinese prevalence rates of eye diseases, growth trends, and major factors. For more detailed content, please refer to the full report.
04 The Chinese Ophthalmology Group has established a segmented diagnosis and treatment system
The Ophthalmology Department of China has established more than ten professional study groups, each making significant contributions to the breadth and depth of ophthalmic academic research, and promoting the internationalization and standardization of ophthalmology in China. Public hospitals play an important role in ophthalmic diagnosis and treatment.
The 'Blue Book' sorts out the sub-specialty groups and research scopes of ophthalmology in China. For more detailed content, please refer to the full report.
05 The demand for ophthalmic equipment has increased driven by general practice services in public and non-public hospitals
In recent years, ophthalmic hospitals in China have developed rapidly. Public hospitals have improved their ophthalmic facilities, while non-public hospitals have laid out serious medical areas for ophthalmology, which is expected to further expand the high-end ophthalmic medical market in China.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the number and changes of ophthalmic hospitals and outpatient clinics in China. For more detailed content, please refer to the full report.
2
Analysis of Ophthalmic Diagnosis and Treatment and Ophthalmic Medical Equipment
01 China has a large base of ophthalmic disease patients, and policies are helping to boost the development of the ophthalmic industry.
Compared to other diseases, the demand for medical equipment in ophthalmology diagnosis and treatment is more prominent. The state strongly supports domestic equipment to boost the development of China's ophthalmic medical device industry.
The 'Blue Book' sorts out the national policies related to the ophthalmic medical device industry. For more detailed content, please refer to the full report.
02 China's strong demand for ophthalmic diagnosis and treatment has catalyzed the rapid development of the domestic ophthalmic industry
The strong demand for diagnosis and treatment and broad market prospects have stimulated innovation in original research products by Chinese enterprises. The industrial chain in the field of ophthalmology in China is becoming increasingly developed and perfected, with many companies listed within the sector. Ophthalmic diagnostic and treatment equipment is developing rapidly, with the potential for domestic advantages to replace imported ones. According to Frost & Sullivan's analysis, the market size of ophthalmic medical devices (including contact lenses and care solutions) in China increased from 178 billion yuan in 2017 to 305 billion yuan in 2021, and is expected to grow to 556 billion yuan and 933 billion yuan respectively by 2025 and 2030.
Note: This is an example of some companies in the industry only.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the industrial chain of ophthalmic medical devices. For more detailed content, please refer to the full report.
03 Classification of Ophthalmic Medical Equipment
Ophthalmic medical equipment can be further divided into ophthalmic diagnostic equipment and ophthalmic therapeutic equipment based on their functional positioning in the ophthalmic medical process. Both play an important and positive role in different diagnostic and treatment fields of ophthalmology.
The 'Blue Book' sorts out the classification and main products of ophthalmic medical equipment. For more detailed content, please refer to the full report.
04 The technology barrier for high-end ophthalmic medical equipment is the highest, and its promotion and popularization can benefit more patients.
The research and development of high-end ophthalmic medical equipment has high barriers, and most of the high-end product market share is occupied by foreign-funded enterprises. The domestic substitution and advantageous substitution of high-end ophthalmic medical equipment in China are expected to further improve the accessibility of ophthalmic diagnosis and treatment, benefiting more patients.
The 'Blue Book' sorts out the market share of major high-end ophthalmic medical equipment and imported products. For more detailed content, please refer to the full report.
3
Market Analysis of High-end Ophthalmic Medical Equipment
01 Market Analysis of Ophthalmic Surgical Microscopes
Ophthalmic surgical microscopes are essential equipment for conducting ophthalmic surgeries. According to the publicly available winning bid data from Chinese public hospitals in 2023, Zeiss products hold an absolute advantage, accounting for 73.1% of the total sales amount; Leica and Topcon products are in the second tier, with market share percentages of 8.1% and 4.9%, respectively. In the future, high-end ophthalmic surgical microscopes will compete around integrated and intelligent functions. The new product that Tuopai Medical will launch in June 2024 is expected to achieve domestic innovation and upgrading, and enter the high-end market.
The 'Blue Book' sorts out the development history, clinical applications, market analysis for 2023, and future prospects of ophthalmic surgical microscopes. For more detailed content, please refer to the full report.
02 Market Analysis of Ophthalmic Optical Coherence Tomography (OCT/OCTA)
Optical coherence tomography (OCT) in ophthalmology plays an important role in the diagnosis of eye diseases. According to the publicly available winning bid data from Chinese public hospitals in 2023, Tuopai Medical's OCT products ranked first in terms of both the number of winning bids and average winning bid price, accounting for 26.6% of the total sales amount. Domestic brands are gradually achieving 'advantageous substitution' for imported products. At the same time, the incremental growth of domestic brands in the underserved market cannot be ignored, and it is foreseeable that future ophthalmic OCT products are expected to achieve a higher degree of localization.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the development history, clinical applications, 2023 market analysis, and future prospects of ophthalmic optical coherence tomography scanners. For more detailed content, please refer to the full report.
03 Fundus camera market analysis
Fundus cameras are widely used in ophthalmic screening and diagnosis, with imported ultra-wide-angle fundus cameras leading the market. According to the publicly available winning bid data for Chinese public hospitals in 2023, the total sales market share of OPTEL and Zeiss was 38% and 26.8%, respectively. Domestic products have been gradually launched, with Weiqing already occupying a certain market share. The new product of Tuopai has also been released. Coupled with other domestic brands such as Yaoshi, it is believed that the localization process of products in this field will accelerate further in the future.
The 'Blue Book' sorts out the development history, clinical applications, market analysis for 2023, and future prospects of fundus cameras. For more detailed content, please refer to the full report.
04 Market Analysis of Optical Biological Measuring Instruments
Optical biometric instruments provide multi-dimensional ocular biometric data. The optical biometric instruments used by hospitals for cataract surgery diagnosis and complex refractive disease diagnosis are dominated by Zeiss. According to the publicly available winning bid data for Chinese public hospitals in 2023, the total sales amount of various models of the Zeiss IOL-MASTER series accounted for 57.5%. At the same time, domestic brands in this field are gradually catching up. Domestic brands represented by Sowei, Motin, Wanlingbangqiao, and New Vision are gradually opening up the market, bringing a large sales scale with their high cost-performance advantage and occupying over 15% of the market share. The launch of the 'Ziwu' series by Tuopai has become the starting point for domestic biometric instruments to challenge the high-end market. It is believed that in the next three years, whether in the hospital market or optometry market, domestic biometric instrument products will gradually become mainstream and drive continuous growth in this field.
Source: Literature search, Frost & Sullivan analysis
The 'Blue Book' sorts out the development history, clinical applications, market analysis for 2023, and future prospects of ophthalmic optical biometry instruments. For more detailed content, please refer to the full report.
05 Analysis of Femtosecond Laser Market
Femtosecond lasers are widely used in refractive surgery and cataract surgery. According to data analysis by Frost & Sullivan, in 2023, the total sales and installations of various femtosecond laser devices in China were about 300 units; using these devices, there were approximately 2 million femtosecond refractive surgeries and about 50,000 femtosecond laser cataract surgeries. Brands such as Zeiss and Alcon occupy a dominant market position. Among them, the technology barrier for full femtosecond laser devices is extremely high, and currently Zeiss holds an absolute market position globally. Many domestic enterprises have also accelerated the research and development of full femtosecond laser devices, and domestic products such as Xianwei Vision are expected to achieve breakthroughs.
The 'Blue Book' sorts out the development history, clinical applications, market analysis for 2023, and future prospects of femtosecond lasers. For more detailed content, please refer to the full report.
06 Market Analysis of Transluminal Excision Biopsy
The femtosecond excimer laser cataract and phacoemulsification (FEMT) integrated machine can be used to treat a variety of ophthalmic diseases, but it has high technical barriers. Global suppliers are mainly from Europe and America. According to the publicly available winning bid data for public hospitals in China in 2023, Aierkang's Constellation series products had the highest market share, reaching 47.9%, occupying a dominant position in the market; Dr. Brown ranked second with a market share of 29.6%; and Godreder ranked third with a market share of 16.1%. Currently, there are no domestic brands in the field of femtosecond excimer laser cataract and phacoemulsification integrated machines on the market. Domestic companies such as Xiran and Tupei are making arrangements, indicating significant potential for domestic substitution in the future.
The 'Blue Book' sorts out the development history, clinical applications, market analysis for 2023, and future prospects of the super-luminescent excimer lithotripter (SLExcimer). For more detailed content, please refer to the full report.
4
Introduction to Some High-End Ophthalmic Medical Equipment Industry Companies
Zeiss
Carl Zeiss AG is a German enterprise brand manufacturing optical and optoelectronic equipment, headquartered in Oberkochen, Germany. It was founded by Carl Zeiss in 1846 in Jena, Germany. Zeiss is committed to developing, producing, and marketing cutting-edge innovative industrial measurement and quality assurance solutions for customers, microscope solutions for the fields of biology and materials science, as well as medical technology solutions for ophthalmology and microsurgery. In addition, Zeiss uses its new interdisciplinary business model to continuously drive the development of optics and related fields. Currently, Zeiss' operations span nearly 50 countries around the world, with more than 60 sales and service institutions, 35 research and development institutions, and 35 production facilities. Zeiss entered China in 1957, with its Greater China headquarters located in the Shanghai Pilot Free Trade Zone, employing about 7,000 people. The Chinese region is one of the markets where Zeiss Group's business is growing rapidly.
Aierkang
Alcon, founded in 1945 with its headquarters located in Geneva, Switzerland, is one of the world's large-scale ophthalmic care equipment companies. As a global leader, Alcon operates directly in 56 countries and serves patients in over 140 countries. Alcon has a rich portfolio of ophthalmic products. Alcon's main business areas are divided into two major segments: ophthalmic surgery and vision care, with complementary business advantages in these two fields.
Tuopei Medical
Tuopai Medical was established in 2017. Its core technology is derived from the transformation of Tsinghua University's scientific and technological achievements and has been cultivated and incubated by the Tsinghua Institute of Technology. The core technology team of Tuopai Medical consists of dozens of teachers and students from various majors such as electronics, life sciences, and precision instruments at Tsinghua University. Relying on the Tsinghua technology platform, they have developed a series of globally leading high-end ophthalmic medical devices. The company currently has a scale of over 300 people, including more than 100 R&D team members, with an annual R&D investment of nearly 100 million yuan. Tuopai Medical has research and development centers in Beijing and Shanghai, as well as manufacturing bases in Beijing, Suzhou, and Tianjin.
The 'Blue Book' introduces some companies in the high-end ophthalmic medical equipment industry, including company profiles, layout of ophthalmic business segments, and main products of ophthalmic medical equipment. For more detailed content, please refer to the full report.
